General Introduction {#Sec1}
====================

The prevention of the plaque-related diseases, dental caries and the periodontal diseases, normally involves the non-specific control of dental plaque as this is the initiating factor. This is carried out to maintain levels of dental plaque compatible with health and thus prevent the breakdown of microbial homeostasis (dysbiosis) concomitant with disease risk. However, the individual response of the host and other confounding factors can influence disease initiation and progression. Antimicrobial and more general antiplaque compounds in oral care products represent a significant complement to mechanical plaque control. Such approaches should preferably reduce oral biofilm formation without affecting the biological equilibrium within the oral cavity, which is inhabited by approximately 1000 different species of bacteria at 10^8^--10^9^ bacteria per mL saliva or mg dental plaque \[[@CR1]\]. However, with ever increasing resistance to antibiotics and a desire from the general public for more 'natural' therapies, there is a need to minimise antibiotic use and develop novel treatments for oral diseases that do not involve conventional antimicrobial agents \[[@CR2]\]. Preventive approaches based upon the restoration of the microbial ecological balance, rather than elimination of the disease associated species, have been proposed \[[@CR3]\]. These include the use of prebiotics to promote health-associated bacterial growth or the use of probiotic bacteria with associated benefits. As regards the possible side effects of oral probiotics, these are likely to be mild in healthy individuals and possibly digestive as observed with those used to control intestinal disease \[[@CR3]\]. In theory, they could cause systemic infections that require treatment with antimicrobial agents, particularly in individuals with underlying health conditions.

Probiotics---Introduction {#Sec2}
=========================

Probiotics, by definition are viable microorganisms which, when administered in adequate amounts, provide a health benefit to the host. This approach has successfully been used to control intestinal diseases and appears to act through colonisation resistance and/or modulation of the immune system \[[@CR2]\]. Likewise, studies are now suggesting that probiotics have the potential to modify the oral microbiota and are being investigated to prevent or treat diseases of the oral cavity, such as dental caries and the periodontal diseases, which are associated with a shift in the microbial composition and activity of the biofilm, and the resulting reaction of the host \[[@CR2]\]. Strains belonging to the *Lactobacillus*, *Streptococcus* and *Bifidobacterium* genera are most commonly investigated as regards probiotics. Species within these taxa are members of the normal microbiota found within the gastrointestinal tract with some species preferentially colonising the oral cavity. With regards to periodontitis, there are health- and disease-associated *Streptococcus* spp., while species from the aforementioned three genera have all been associated with dental caries \[[@CR3]\]. Therefore, when selecting suitable probiotic species, the normal oral habitat and association with health should be considered.

Experimental studies and clinical trials have demonstrated that certain gastrointestinal bacteria, including *Lactobacillus* and *Bifidobacterium* spp., have the potential to control the growth of oral microorganisms, including the cariogenic streptococci \[[@CR4]\]. Within the oral cavity, mechanisms of probiotic action can possibly be suggested from previous gastrointestinal studies, whereby the introduction of microorganisms as a therapeutic tool for the control of oral and dental disease could act as follows \[[@CR4]\]:A.Direct interactions within dental plaque (colonisation resistance). This mechanism could possibly include the disruption of plaque biofilm formation through competition for binding sites on host tissues and other bacteria, and through competition for nutrients. The production of antimicrobial compounds by probiotic species that inhibit other oral bacteria may also be a significant mechanism. It is known that lactic acid bacteria produce a range of antimicrobial agents including organic acids, hydrogen peroxide, peptides, bacteriocins and anti-adhesion molecules \[[@CR4]\].B.Indirect probiotic actions within the oral cavity, including the modulation of both innate and adaptive immune function. Within this context, it is possible that lactic acid bacteria can interact with immunocompetent cells, such as macrophages and T-cells, leading to an alteration in the production of cytokines and subsequent effects on overall immunity \[[@CR4]\]. For example, lactobacilli are able to elicit a transient reduction in IL-8 secretion in the gingival crevicular fluid of subjects with mild gingival inflammation. Beyond the modulation of immune responses, some probiotic species are able to enhance mucin production and barrier function, upregulate host defence peptides, promote angiogenesis and wound healing \[[@CR5]\].

Periodontal Diseases {#Sec3}
====================

Periodontal diseases (periodontitis and gingivitis) are a group of inflammatory pathologies of the periodontium that lead to loss of teeth principally due to dysregulated, immune-mediated destruction of the periodontal ligaments and tooth supporting structures \[[@CR6], [@CR7]\]. A dysbiotic oral microbiota is associated with periodontitis and in the most common forms of this disease namely, chronic and aggressive periodontitis is thought to play an active role in the pathogenesis by promoting chronic dysregulated inflammation which in turn sustains the dysbiotic microbial ecology \[[@CR8], [@CR9]\].

Probiotics as an Adjunct for Clinical Periodontal Treatment {#Sec4}
-----------------------------------------------------------

A probiotic that could alter the oral microbial ecology may be a useful tool in the clinical management of periodontitis, with the potential to offer two-fold benefits \[[@CR10]\]. Firstly, to combat dysbiosis by competitive inhibition of periodontal pathogens, and thereby reducing the overall immunogenicity of the oral microbiota. Secondly, to modulate active disease-associated immune/inflammatory pathways to reduce the destructive inflammation of periodontitis, and lead to immune homeostasis that could be maintained by the host in the long term.

Clinical studies in humans that have explored treatment of the periodontal diseases using probiotic therapy unaided by clinical treatment measures, have reported modest overall benefits such as reduction of gingival bleeding and probing depth \[[@CR11]\]. However, studies that involved probiotics as an adjunct to clinical periodontal treatment report a more marked improvement in the clinical status of patients compared to clinical treatment alone (Table [1](#Tab1){ref-type="table"}). This could be an important avenue for probiotics in lieu of antibiotics in periodontal treatment to help reduce the overall burden of antibiotic resistance \[[@CR28], [@CR29]\]. Despite existing heterogeneity in the clinical studies that investigated use of probiotics in the management of gingivitis or periodontitis, meta-analyses in the literature have found some overall support for the use of probiotics \[[@CR30], [@CR31]•\]. However, there are several aspects to probiotic therapy that need to be better understood before routine use in managing gingivitis and periodontitis can be recommended \[[@CR32]\]. These include: (i) length and mode of treatment to prevent the periodontal microbiota from reverting to a dysbiotic ecology at termination of treatment (ii) characterising the possible in vivo cariogenic effects of the probiotic strains which may manifest during the treatment period (iii) elucidating the possible systemic risks of administering probiotic strains to individuals with systemic pathologies that involve mild to moderate immune suppression.Table 1Summary of the clinical studies that evaluated various probiotic strains for treatment of chronic periodontitis or gingivitisReferenceProbiotic strain(s) (mode of delivery)Study populationDesignProbiotic treatmentMonitoringClinical measurementsPlaque indicesBleeding indicesProbing depthClinical Attachment Loss\[[@CR12]\]*Lactobacillus plantarum Lactobacillus brevis Pediococcus acidilactici* (tablet)Gingivitis minor attachment loss \< 2 mmParallel-groupTwo tablets/day for 6 weeksBaseline and week 6ns↓ AngBS ↓ GI----\[[@CR13]\]*Lactobacillus reuteri* DSM 17938 and ATCC PTA 5289 (lozenge)Gingivitis pregnant women in 3rd trimesterParallel-groupTwo lozenges/day for 7 weeksBaseline and week 7↓ PI↓ GI----\[[@CR14]\]*Lactobacillus salivarius Lactobacillus reuteri* (capsule/direct)Chronic periodontitis CAL ≥4 mm ≥ 4 sites with PD ≥5 mmParallel-group SRP+adjunctTwice/day for 14 days rinse with capsule direct subgingival delivery at baseline, weeks 1, 2 and 4.Baseline, months 1 and 3↓ PI up to 3 months↓ GI and BI up to 3 months↓ ns↓ ns\[[@CR15]\]*Lactobacillus rhamnosus* (sachet)Chronic periodontitis ≥ 5 teeth with PD ≥ 5 mm and CAL ≥3 mmParallel-group SRP+adjunct1/day drink of sachet contents for 3 monthsbaseline, 6 weeks, and months 3, 6, 9 and 12↓ ns at 12 monthsns↓ ≥ 6 mm sites↓ ns at 12 months\[[@CR16]\]*Lactobacillus plantarum* L-137 (heat killed; capsule)'Chronic periodontitis' patients undergoing therapy ≥1 site PD ≥4 mmParallel-group SRP+adjunct1/day for 12 weeksBaseline and weeks 4, 8 and 12ns (PI)↑ BOP ns up to 12 weeks↓ sites ≥ 4 mm ns--\[[@CR17]\]*Bacillus subtilis Bacillus megaterium Bacillus pumulus* (toothpaste, toothbrush cleaner, mouth rinse)GingivitisParallel-group2/day brushing with probiotic toothpaste and 1/day mouth rinse for 8 weeks (toothbrush stored in cleaner till next use)Baseline and week 8ns (PI)ns (GI)----\[[@CR18]\]*Streptococcus oralis* KJ3 *Streptococcus uberis* KJ2 *Streptococcus rattus* JH145 (tablet)Chronic periodontitis (severe)Parallel-group SRP+adjunct2/day dissolving tablet on tongue 12 weeksBaseline and weeks 4, 8, 12 and 24PI ↓ up to 24 weeks↓ GI and ↓ BOP ns up to 24 weeksns up to 24 weeksns up to 24 weeks\[[@CR19]\]*Lactobacillus reuteri* (lozenge)Chronic periodontitis radiographic evidence of horizontal bone loss; ≥ 2 teeth per quadrant at 5--7 mm PD; ≥ 2 GI per quadrantParallel-group SRP+adjunct2/day for 3 weeks.Baseline and days 21, 90, 180 and 360PI ↓ up to 360 days↓ GI and BOP up to 360 days↓ ≥ 5 mm sites up to 360 days↓ up to 360 days\[[@CR20]\]*Lactobacillus brevis* CD2 (lozenge)Experimental gingivitisParallel-group abstained from oral hygiene after cleaning period for 2 weeks3/day for 2 weeksBaseline, 3, 7, 10 and 14 daysns (PI)↓ BOP at Day 10 only.----\[[@CR21]\]*Lactobacillus reuteri* ATCC PTA 5289 (tablet)Moderate chronic periodontitis CAL \> 5 mm and PD \> 4 mm in ≥ 2 adjacent teethparallel-group SRP+adjunct2/day (time period not clear)Baseline, end time point 2 weeks after probiotics terminatedns (PI)↓ SBI↓ mean PD↓\[[@CR22]\]*Lactobacillus reuteri* ATCC 55730 and ATCC PTA 5289 (lozenge)Experimental gingivitis (female participants only)Cross over professional tooth cleaning during a washout period of 2 weeks.2/day for 3 weeksBaseline and 21 daysns (PI)ns (GI and BOP)----\[[@CR23]\]*Lactobacillus reuteri* DSM 17938 and ATCC PTA 5289 (lozenge)Chronic periodontitis (moderate-severe)Parallel-group Full mouth disinfection and SRP+adjunct2/day for 12 weeksBaseline and week 3, 6, 9 and 12↓ ns at 3, 9 and 12 weeks ↓ at 6 weeks↓ ns at 3, 6 and 9 weeks ↓ at 12 weeks↓ ns mean PD ↓ ≥ 5 mm PD at 12 weeks↓ ns\[[@CR24]\]*Lactobacillus reuteri* ATCC 55730 and ATCC PTA 5289 (tablet)Chronic periodontitisParallel-group no professional treatment1/day for 30 daysBaseline and day 30↓ at day 30↓ BOP at day 30↓ 4--5 mm PD ↓ ≥ 6 mm PD at day 30.--\[[@CR25]\]*Lactobacillus reuteri* DSM 17938 and ATCC PTA 5289 (tablet)Gingivitis \> 1 gingival index and no CALParallel-group teeth polished at baseline1/day for 28 days.Baseline, week 4 and 8ns (mean PI)ns (mean GI)----\[[@CR26]\]*Lactobacillus casei '*Shirota' (milk)Experimental gingivitisParallel-group scaling and polishing 2 weeks before baseline1/day drink (65 mL) for 28 daysBaseline and day 1, 3, 5, 7 and 14Mean PI at baseline for two groups were different.↓ BOP up to 14 days GI values were significantly different at baseline----\[[@CR27]\]*Lactobacillus reuteri* DSM 17938 and ATCC PTA 5289 (lozenge)Chronic periodontitis PD 5--7 mm and radiographic bone loss evidenceSplit-mouth SRP+adjunct2/day for 3 weeks; 3 week gap after SRP at baselineBaseline, week 3 and 6↓ PI score at week 6↓ GI score at week 6↓ mean PD at week 6↓ at week 6*PI* plaque index, *GI* gingival index, *GBI* gingival bleeding index, *AngBS* angulated bleeding score, *BI* bleeding index, *SBI* sulcus bleeding index, *BOP* bleeding on probing (% of sites), *PD* probing depth, *CAL* clinical attachment loss, *SRP* scaling and root planing, *ns* not significant↓decrease↑increase

Probiotics in Remodelling the Periodontal Ecosystem {#Sec5}
---------------------------------------------------

The periodontium provides several unique niches for microbial colonisation, with the subgingival niche being the most studied in relation to the periodontal diseases \[[@CR33], [@CR34]\]. Most studies investigating the role of probiotics in modifying the microbial ecology in the periodontium in vivo have endeavoured to measure specific microbial species considered to be 'periodontopathogens' or key microorganisms in oral biofilm development. In a study using lozenges containing *Lactobacillus reuteri* strains as an adjunct to scaling and root planing treatment of chronic periodontitis, significant reductions in the abundance of *Porphyromonas gingivalis* in saliva, subgingival and supragingival plaque were reported in the treatment group. However, no significant reductions in the overall plaque scores compared to the group who underwent clinical treatment and consumed placebo lozenges were demonstrated \[[@CR23]\]*.* Streptococcal probiotic strains evaluated as adjuncts to clinical treatment of chronic periodontitis showed significant reduction in plaque scores, in addition to reductions of *Tannerella forsythia* and *Prevotella intermedia* in supragingival plaque and saliva, respectively \[[@CR18]\]. Microbiological culture of subgingival plaque in a split-mouth study with *L. reuteri* as an adjunct to conventional treatment in chronic periodontitis patients has also shown reductions in *Aggregatibacter actinomycetemcomitans, P. gingivalis* and *P. intermedia* \[[@CR27]\]*.* Whilst the differences in dental plaque scores between these studies may relate to the probiotic strain used and differences in treatment modality, these data suggest that probiotic strains could alter the community structure of the supragingival and subgingival plaque in chronic periodontitis, either directly by inhibiting disease-associated taxa such as *Fusobacterium nucleatum* and *Prevotella intermedia* or indirectly by inhibiting the keystone pathogen *P. gingivalis*.

Probiotic treatment of gingivitis as an adjunct to professional mechanical plaque removal has also shown significant reductions in the major periodontopathogens namely, *P. gingivalis*, *A. actinomycetemcomitans* and *T. forsythia* in the subgingival plaque compared to placebo \[[@CR12]\]. While treatment of gingivitis with *L. reuteri* lozenges alone has been reported to significantly reduce *P. gingivalis* and *A. actinomycetemcomitans* abundance in the subgingival plaque, *P. gingivalis* was reported to recover and show an increase in prevalence in the subgingival plaque within 4 weeks after the end of treatment \[[@CR25]\]. In a study that investigated twice per day probiotic *L. reuteri* consumption for 3 weeks as an adjunct to clinical treatment of chronic periodontitis, a significant reduction in the proportion of obligate anaerobes in the subgingival plaque was observed up to 21 weeks after the end of the probiotic course compared to placebo, with a return to baseline levels at the 1 year follow-up \[[@CR19]\]. These observations suggest that while currently available probiotics could alter the periodontal microbial ecology to resemble a more health-associated ecology during treatment of gingivitis or chronic periodontitis, this effect is not maintained by the host in the long term. It has been suggested that this could be due to the low persistence of these probiotic strains in the oral cavity, as the majority used are not oral isolates, and those currently in use as probiotics are rare taxa in themselves and thus more susceptible to fluctuations in the oral environment \[[@CR35]\]. Further, the lack of more comprehensive ecological surveys using established high throughput 16S rDNA sequencing platforms in the literature limits the current understanding into the nature of community-wide changes exerted by the probiotic strains in the periodontal niches during treatment.

Probiotics in the Maintenance of Periodontal Health {#Sec6}
---------------------------------------------------

Ecological surveys reported in studies that investigated probiotics for preventative oral care have provided some insights into the changes occurring in the oral microbiome of healthy individuals consuming probiotic products. A course of *Lactobacillus rhamnosus* GG and *Bifidobacterium animalis* ssp. *lactis* containing lozenges taken by healthy individuals were reported to show no significant changes in the salivary ecology compared to baseline as profiled by the human oral microbe identification microarray, but did allow an improvement in gingival health \[[@CR36]\]. A study that employed next generation sequencing of salivary microbiota in healthy individuals consuming a transconjugant *Streptococcus salivarius* M18 also reported no significant changes in the overall ecology, with the probiotic streptococcus forming a large proportion of the total indigenous *S. salivarius* population in some individuals \[[@CR37]•\].

However, significant health-associated changes in the supragingival plaque microbiota were reported in a study that employed *L. reuteri* as a prophylactic probiotic, suggesting niche-specific ecological changes, in addition to effects specific to the probiotic strain used \[[@CR38]•\]. After a 12-week course of the probiotic, the supragingival microbiota was reported to be associated with an increased relative abundance of *Neisseria subflava*, *Campylobacter consisus*, *Granulicatella adicaens*, *Bergeyella* sp. HOT322, *Streptococcus oralis* and other health-associated oral taxa including nitrate-reducing species*.* The baseline samples showed an abundance of disease-associated taxa including *Streptococcus mutans*, *Fusobacterium periodonticum*, *F. nucleatum* ssp. *vincentii*, *S. anginosus*, *Eikenella* spp. and *Neisseria mucosa*. However, at the 1-month follow-up after termination of probiotic use, the community structure was found to revert to baseline, with a significant reduction in the prevalence of *L. reuteri* in the saliva.

Immunomodulatory Activities of Probiotics in Disease and Health {#Sec7}
---------------------------------------------------------------

Anti-inflammatory activity is a key effect of probiotics observed in vitro and as demonstrated in animal model studies, further supported by human studies in non-oral contexts \[[@CR39], [@CR40]\]. The systemic immunomodulatory effects of gut based probiotics may also have a protective effect in relation to periodontitis as demonstrated in a mouse model \[[@CR41], [@CR42]\]. In addition, it has been shown that probiotics can have a positive effect on oral health by means of reduced osteoclastic activity in a murine orthodontic tooth movement model \[[@CR43]\].

In human experimental gingivitis studies with *L. reuteri* or *L. brevis* lozenge use, no marked differences in the gingival crevicular fluid (GCF) levels of cytokines such as TNF-alpha, IL-1 beta, CXCL8, CXCL10, CCL4, MMP-8 and prostaglandin E2 concentrations were reported compared to placebo \[[@CR20]•, [@CR22]\]. While elevated IL-6 and lowered IL-18 concentrations were reported in these studies, no significant changes in the clinical parameters assessed in the individuals were found \[[@CR22]\]. However, probiotic *L. reuteri* as an adjunct for clinical treatment of chronic periodontitis was reported to yield more marked anti-inflammatory effects in showing a reduction in TNF-alpha, IL-1 beta and IL-17 concentrations in the GCF of patients, allied to an improvement in clinical aspects of disease such as gingival bleeding index and probing depth \[[@CR21]\]. There is limited evidence that some of these effects could be maintained in the medium term, as another study that followed chronic periodontitis patients for up to a year after a 3-week course of *L. reuteri* lozenges after scaling and root planning procedures found a reduction in GCF matrix metalloproteinase-8 (MMP-8) and an increase of tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) up to 180 days \[[@CR44]\]. These studies suggest that immune modulation is detectable within GCF when probiotics are used in conjunction with professional mechanical plaque removal and a sustained oral hygiene regimen, and this is exhibited along with an improvement in clinical oral health parameters.

Animal studies have shown a more pronounced activity for probiotics; however, these studies treat disease without mechanical dental plaque removal interventions. It has been shown that *Bifidobacterium animalis* ssp. *lactis* could confer protection from bone loss when administered subgingivally to ligature-induced periodontitis sites in a murine model \[[@CR45]\]. Other studies have also shown protective effects against bone loss with *Bacillus subtilis*, *Bacillus licheniformis* and *L. brevis* CD2 in murine periodontitis models \[[@CR46]--[@CR48]\]. Recent in vitro studies continue to elucidate the mechanisms of probiotic immune modulation, showing that probiotic lactobacilli could abolish CXCL8 attenuation by *P. gingivalis*, and promote Th1 and Th17 responses \[[@CR49], [@CR50]\]. An 8-species probiotic mixture containing lactobacilli, bifidobacteria and streptococcus has been shown to polarise human macrophages towards the M1-phenotype \[[@CR51]\].

Halitosis (Oral Malodour) {#Sec8}
=========================

Intra-oral halitosis is a common condition, and is known to be associated with periodontitis with the putrefactive activity of the tongue microbiota playing a major role in producing volatile malodorous compounds in both pathological (disease-associated) and physiological (transient non-disease associated) halitosis \[[@CR52], [@CR53]\]. Due to this distinction in the aetiology of intra-oral halitosis, probiotics that could help maintain periodontal health could also serve to combat pathological halitosis, while helping to maintain a healthy tongue ecology as, the more difficult to reach areas of the tongue for oral hygiene such as the dorsal posterior surface to the circumvallate papillae are known to harbour a high abundance of anaerobic gram-negative bacterial species associated with malodour \[[@CR54]\]. However, it is known that the tongue is a more distinct niche than the periodontal niches in terms of species that normally colonise suggesting the requirement of niche-specific adaptations, and probiotic strains targeted to colonise the periodontal niches may not readily colonise the tongue to exert health-promoting effects \[[@CR55], [@CR56]\].

One of the earliest probiotic strains proposed to target oral malodour and fulfilling the above criteria was the bacteriocin-producing strain *S. salivarius* K12, which reduced breath volatile sulfur compound (VSCs) concentrations in individuals who consumed the probiotic lozenges after pre-treatment with a chlorhexidine rinse \[[@CR57]--[@CR60]\]. This strain has also been shown to inhibit in vitro growth of some oral malodour associated bacterial species such as *Solobacterium moorei*, *Parvimonas micra* and *Eubacterium sulci* \[[@CR60]\]*.* Studies using *Lactobacillus salivarus* WB21 for a short course by individuals with oral malodour found that periodontal health improved in addition to a reduction in breath VSCs \[[@CR61], [@CR62]\]. However, whilst this study found a reduction in salivary abundance of the VSC producing species *F. nucleatum*, no significant differences in the organoleptic scores between treatment and placebo were found. Favourable anti-VSC activities have been demonstrated with in vitro evaluations using *Weisella cibaria*, *Enterococcus faecium* and *Streptococcus thermophilus*, although these are non-oral strains \[[@CR63]--[@CR65]\]. Lactobacilli that have shown positive effects with regards to treating periodontitis and promoting oral health have been evaluated in human clinical studies to reduce oral malodour. It has been shown that reuterin-like compounds could suppress VSC production by periodontopathic bacteria such as *F. nucleatum* and *P. gingivalis*, in addition to downregulation of the enzyme (methionine γ lyase) responsible for production of the VSC methanethiol in the latter \[[@CR66]\]. However, *L. reuteri* consumption was not found to reduce organoleptic scores, and a cysteine rinse evaluation did not produce a significant difference to placebo \[[@CR67]\]. Individuals with persistent oral malodour treated with *L. brevis* CD2 lozenges failed to show an improvement in organoleptic scores or breath VSC concentrations \[[@CR68]\]. Consumption of *Lactobacillus casei* Shirota milk also did not show significant changes in the breath VSC concentration or organoleptic scores, despite presence of the probiotic strain in the tongue plaque during treatment \[[@CR69]\].

These studies highlight that current probiotics show very limited ability to control oral malodour in vivo. There is a need to screen available strains for adherence to the tongue and to demonstrate tongue colonisation in clinical studies \[[@CR70]\]. It may also be useful to show effects of probiotic strains targeted to the periodontal niches, on the tongue ecology. Further, more abundant tongue-associated indigenous oral strains could be screened for probiotic activity to help with colonisation and maintenance of healthy tongue ecology. Conversely, understanding the persistence mechanisms of the more disease-associated oral microbial species could also help in construction of novel low-abundance probiotic strains with enhanced persistence.

Nitrate-Reducing Bacteria as Probiotic Agents {#Sec9}
=============================================

Nitric oxide (NO) is a labile and highly reactive gas which is known to be generated endogenously through the activity of NO synthases from mammalian cells and contributes to host defence against a number of pathogenic microorganisms \[[@CR71]\]. The generation of NO, through the action of microbial nitrate reductases on salivary nitrate, has also been recognised as a significant source of this molecule \[[@CR72]•\]. Nitrate absorbed from ingested dietary sources, especially green vegetables, is actively concentrated by the salivary glands so that concentrations in the saliva are approximately 10 times those found in plasma \[[@CR73]\]. Nitrate is then rapidly converted to nitrite in the mouth by bacteria, through the activity of nitrate reductase enzymes. It has been shown that the bacteria responsible for nitrate reduction reside within the crypts of the tongue, where they are maintained in an anaerobic environment and reduce nitrate to nitrite during respiration \[[@CR74]\]. The function of the salivary concentration of nitrate and reduction to nitrite is not fully established but it has been shown that the high concentrations of nitrite formed in saliva will, when acidified in the stomach, produce nitrous acid and NO in sufficient concentrations to kill *Escherichia coli* and other enteric pathogens \[[@CR75]\]. Additionally salivary nitrite will encounter the acid environment around the teeth provided by acidogenic bacteria such as *Lactobacillus* spp. and *Streptococcus mutans*. In vitro studies have shown that acidified nitrite will significantly decrease the growth and survival of these bacteria \[[@CR76]\]. It is thus hypothesised that increasing nitrate intake may be important in suppressing the growth of acid-forming bacteria and thereby protect the teeth against caries.

A relationship between dental caries and levels of nitrate and microbial nitrate reductase activity in the saliva of children has been established. Compared with control subjects, a reduction in caries experience was found in patients with high salivary nitrate and high nitrate-reducing ability \[[@CR77]\]. Production of nitrite from salivary nitrate by commensal nitrate-reducing bacteria (NRB) may thus limit the growth of cariogenic bacteria as result of the production of antimicrobial oxides of nitrogen, including NO. This lends support to the hypothesis that a high nitrate-reducing flora may also be of benefit in the protection against dental caries. In recent oral microbiome studies based upon bacterial 16S rDNA sequencing using the HOMINGS methodology and Minimum Entropy Decomposition data analysis, the stability of the tongue microflora in health, particularly the NRB including *Rothia* spp. was shown to be associated with oral health \[[@CR78]\].

The identification of NRB as commensal inhabitants may now provide the basis for probiotic therapy in mammals susceptible to oral infections. In man, the new-born infant is at first edentulous and has a microbial flora characteristic of this condition. Studies have shown that the frequency of isolation of NRB significantly increases after the teeth begin to erupt at about the age of 6 months \[Allaker; unpublished observations\]. Thus, probiotic therapy could be accomplished by the introduction of NRB into neonates, which have yet to acquire these bacteria or adults after the use of broad-spectrum antibiotics to firstly reduce tongue populations of bacteria. Bacterial metabolism of nitrate to nitrite within the oral cavity and the subsequent formation of biologically active nitrogen oxides are unlikely to have wider undesirable effects; however, disruption of the intestinal microflora remains a possibility.

It is well established that salivary glands may respond to periodontitis through the enhancement of the protective effects of saliva \[[@CR79]•\]. An increase in nitrate secretion and subsequent increase in salivary nitrite through the activity of NRB has been found to be higher in subjects with periodontitis and thus may contribute to this protection in response to the inflammatory process \[[@CR79]•\]. NO levels in saliva and gingival crevicular fluid have been found to be higher in patients with aggressive periodontitis as compared to gingivitis \[[@CR80]\]. This could arise both through an increase in salivary nitrate and subsequent microbial reduction and also through the activity of host NO synthases where the upregulation of enzyme activity in response to periodontal bacteria has been shown \[[@CR81]\]. Therefore the use of probiotics to enhance oral NO production through both nitrate reduction and upregulation of synthase activity may be beneficial in the control of bacteria associated with dental caries and periodontitis. However, the role of NO is both positive as an antimicrobial agent and negative as regards its inflammatory effects if present in high enough concentrations. Indeed, the probiotic strain *Lactobacillus brevis* CD2 has been shown to delay the development of gingivitis in a clinical model by the downregulation of the inflammatory cascade via the competitive utilisation of the NO substrate arginine \[[@CR20]•\].

Dental Caries {#Sec10}
=============

The prevalence of dental caries continues to increase worldwide and remains the most common chronic condition during childhood. The assessment of the use of probiotics in the control of dental caries has been limited by the number of subjects needed, prolonged treatment duration and high cost. Most studies have measured counts of *Streptococcus mutans* in saliva or dental plaque; and/or the flow, pH or buffering capacity of saliva. However, only a limited number of studies have used clinical indicators, for both dental caries and the periodontal diseases to demonstrate the efficacy of probiotics. A recent systematic review and meta-analysis provide a useful guide to clinical decision making and direction for further research \[[@CR31]•\].

Strains of *Lactobacillus rhamnosus*, *L. casei*, *L. reuteri* and *Bifidobacterium* spp. have all demonstrated the potential to alter colonisation of cariogenic bacteria and thus prevent dental caries \[[@CR82]\]. To achieve optimal effects, simultaneous use of multiple species or strains may be required as described in human studies using *Streptococcus oralis*, *S. uberis* and a lactic acid-deficient variant of *S. rattus*, whereby the probiotic mouthwash used was able to markedly affect the levels of cariogenic bacteria in saliva together with periodontal pathogens in subgingival plaque \[[@CR83], [@CR84]\]. It is also hypothesised that those oral commensals associated with health are likely to be more effective as probiotic species than the traditional gut-associated probiotic species in terms of ability to colonise, health-promoting functions, biocompatibility and necessary dosage. *Streptococcus dentisani*, a species isolated from individuals who are caries-free, could be a particularly beneficial probiotic species through its production of bacteriocins and acid buffering capacity \[[@CR35]\]. As reported in a 90-day clinical study, the probiotic strain *Streptococcus salivarius* M18, also a producer of bacteriocins, was able to reduce caries development in children as assessed by a number of caries-related risk factors \[[@CR85]\].

'Replacement therapy' based upon biotechnological approaches has also been investigated. Techniques used include gene inactivation to remove harmful metabolites and the incorporation of genes to encode for antimicrobial compounds, for example bacteriocins. *S. mutans* has been considered for replacement therapy in the control of dental caries. A strain of *S. mutans* was made lactate dehydrogenase deficient by the deletion of virtually all of the genetic sequence encoding this enzyme. To compensate for the resulting metabolic imbalance, an alcohol dehydrogenase gene from *Zymomonas mobilis* was then introduced with no detectable lactic acid being produced from the resulting clone. This strain was also significantly less cariogenic than the parent strain as tested in gnotobiotic- and conventional-rodent models of dental caries. In addition, it was found to colonise the teeth of conventional rats to the same extent as the parent strain using both aggressive-displacement and pre-emptive-colonisation approaches. The clone was also shown to be genetically stable and did not revert to producing acid with in vivo and in vitro test systems \[[@CR86]\]. It has been suggested that this *S. mutans* clone (SMaRT Replacement Therapy product has recently been developed by Oragenics Inc.) could provide a lifetime of protection in humans against dental caries, but may require occasional re-applications.

Conclusions {#Sec11}
===========

Probiotics could have an important role to play in the clinical management of dental caries and the periodontal diseases, although the evidence is less convincing as regards halitosis. Both long-term efficacy and safety of probiotics should be established in preventative or treatment contexts, in order to inform safe clinical recommendations. Studies must determine strain specific and synergistic effects of strains in vitro to help inform in vivo mechanisms. Innovative approaches using oral microbiome transplants could further increase the role of probiotics in personalised treatment, while other approaches that involve use of more abundant indigenous oral strains may yield long-term benefits in the maintenance of health by the host \[[@CR87]\]. Study of the mechanisms involved in the recession of health when oral probiotic loading is concluded may illuminate the role of the host-microbial interface in health.
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